Cesca is a leading regenerative medicine company that develops, commercializes and markets a range of automated technologies for cell-based therapeutics.
Its device division, ThermoGenesis, provides a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology.
Cesca is also leveraging its proprietary AutoXpress® technology platform to develop an automated, functionally-closed CAR-TXpress platform that addresses cellular manufacturing needs in the immuno-oncology field.
July 19, 2016
RegMed investors’ closing bell analysis: Risk aversion pushes the downside even lower
July 7, 2016
RegMed investors’ closing bell analysis: the upside waivered at the mid-day regaining ground at the close
July 6, 2016
RegMed investors’ closing bell analysis: a revolving sector and a positive close
June 27, 2016
RegMed investors’ closing bell analysis: sweating the sell-off damage
June 24, 2016
Lower open expected as UK quits EU; RegMed investors’ pre-open, I am concerned with volatility
June 20, 2016
Higher open expected; RegMed investors’ pre-open, cell therapy needs to grow up faster
June 17, 2016
RegMed investors’ closing bell analysis: keeping score
June 16, 2016
Lower open expected; RegMed investors’ pre-open, BioTime (NYSEMKT: BTX) files for offering
June 15, 2016
RegMed investors’ closing bell analysis: as good as it gets?
June 14, 2016
Lower open expected; RegMed investors’ analysis, what's risk tolerance?
35 companies, 1 interpreter!
Insight, foresight and recommendation
Cesca Therapeutics (KOOL) – January '18 opened at $3.10 and it's beed downhill until February at $2.75 with some upside to $2.95 on 2/16. NOT a believer ...
sellMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2025 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.